ELI LILLY & CO shares rose 4% premarket on June 8 following positive trial data for its next-generation obesity drug, retatrutide. The data suggests the drug could extend the lead of ELI LILLY & CO in the $200B obesity market by matching current top-tier efficacy at lower doses. For investors, these findings reinforce the company's competitive position as drugmakers increasingly compete on patient tolerability and dosing simplicity.

Retatrutide Matches Zepbound Efficacy at Lower Doses